Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?
- PMID: 25101673
- PMCID: PMC4454301
- DOI: 10.1038/cddis.2014.326
Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?
Abstract
Classically, as a transcription factor family, the E2Fs are known to regulate the expression of various genes whose products are involved in a multitude of biological functions, many of which are deregulated in diseases including cancers. E2F is deregulated and hyperactive in most human cancers with context dependent, dichotomous and contradictory roles in almost all cancers. Cancer cells have an insatiable demand for transcription to ensure that gene products are available to sustain various biological processes that support their rapid growth and survival. In this context, cutting-off hyperactivity of transcription factors that support transcription dependence could be a valuable therapeutic strategy. However, one of the greatest challenges of targeting a transcription factor is the global effects on non-cancerous cells given that they control cellular functions in general. Recently, there is growing realization regarding the possibility to target the oncogenic activation of transcription factors to modulate transcription addiction without affecting the normal activity required for cell functions. In this review, we used E2F1 as a prototype transcription factor to address transcription factor activity in cancer cell functions. We focused on melanoma considering that E2F1 executes critical functions in response to UV, an etiological factor of cutaneous melanoma and lies immediately downstream of the CDKN2A/pRb axis, which is frequently deregulated in melanoma. Further, activation of E2F1 in melanomas can also occur independent of loss of CDKN2A. Given its activated status and the ability to transcriptionally control a plethora of genes involved in regulating melanoma development and progression, we review the current literature on its differential role in controlling signaling pathways involved in melanoma as well as therapeutic resistance, and discuss the practical value of weaning melanoma cells from E2F1-mediated transcription dependence for melanoma management.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4454301/bin/cddis2014326f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4454301/bin/cddis2014326f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4454301/bin/cddis2014326f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4454301/bin/cddis2014326f4.gif)
Similar articles
-
Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.Exp Cell Res. 1999 Dec 15;253(2):561-72. doi: 10.1006/excr.1999.4688. Exp Cell Res. 1999. PMID: 10585280
-
MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.Mol Cancer Res. 2011 Apr;9(4):440-7. doi: 10.1158/1541-7786.MCR-10-0344. Epub 2011 Mar 31. Mol Cancer Res. 2011. PMID: 21454377
-
Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.EMBO J. 1997 Sep 1;16(17):5322-33. doi: 10.1093/emboj/16.17.5322. EMBO J. 1997. PMID: 9311992 Free PMC article.
-
[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].Cancer Radiother. 2001 Apr;5(2):109-29. doi: 10.1016/s1278-3218(01)00087-7. Cancer Radiother. 2001. PMID: 11355576 Review. French.
-
E2F - at the crossroads of life and death.Trends Cell Biol. 2008 Nov;18(11):528-35. doi: 10.1016/j.tcb.2008.08.003. Epub 2008 Sep 18. Trends Cell Biol. 2008. PMID: 18805009 Review.
Cited by
-
Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy.Front Pharmacol. 2024 Jul 25;15:1432490. doi: 10.3389/fphar.2024.1432490. eCollection 2024. Front Pharmacol. 2024. PMID: 39119602 Free PMC article. Review.
-
RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer.Exp Mol Med. 2024 Mar;56(3):600-615. doi: 10.1038/s12276-024-01184-4. Epub 2024 Mar 1. Exp Mol Med. 2024. PMID: 38424195 Free PMC article.
-
Comparative transcriptomic analysis of circulating endothelial cells in sickle cell stroke.Ann Hematol. 2024 Apr;103(4):1167-1179. doi: 10.1007/s00277-024-05655-6. Epub 2024 Feb 22. Ann Hematol. 2024. PMID: 38386032
-
HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B.Cell Rep Med. 2023 Nov 21;4(11):101285. doi: 10.1016/j.xcrm.2023.101285. Epub 2023 Nov 10. Cell Rep Med. 2023. PMID: 37951219 Free PMC article.
-
LncRNA LIMp27 Regulates the DNA Damage Response through p27 in p53-Defective Cancer Cells.Adv Sci (Weinh). 2023 Mar;10(7):e2204599. doi: 10.1002/advs.202204599. Epub 2023 Jan 13. Adv Sci (Weinh). 2023. PMID: 36638271 Free PMC article.
References
-
- Kovesdi I, Reichel R, Nevins JR. Identification of a cellular transcription factor involved in E1A trans-activation. Cell. 1986;45:219–228. - PubMed
-
- Polager S, Ginsberg D. E2F—at the crossroads of life and death. Trends Cell Biol. 2008;18:528–535. - PubMed
-
- Mundle SD, Saberwal G. Evolving intricacies and implications of E2F1 regulation. FASEB J. 2003;17:569–574. - PubMed
-
- Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci. 2004;29:409–417. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous